Clinical Trial Detail

NCT ID NCT02923349
Title A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Europe Sàrl
Indications

renal cell carcinoma

melanoma

lung non-small cell carcinoma

endometrial adenocarcinoma

Advanced Solid Tumor

ovarian cancer

Therapies

INCAGN01949

Age Groups: adult senior

No variant requirements are available.